CA2684539A1 - Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma - Google Patents
Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma Download PDFInfo
- Publication number
- CA2684539A1 CA2684539A1 CA002684539A CA2684539A CA2684539A1 CA 2684539 A1 CA2684539 A1 CA 2684539A1 CA 002684539 A CA002684539 A CA 002684539A CA 2684539 A CA2684539 A CA 2684539A CA 2684539 A1 CA2684539 A1 CA 2684539A1
- Authority
- CA
- Canada
- Prior art keywords
- use according
- formoterol
- combination
- microgram
- beclometasone dipropionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title claims abstract 9
- 208000006673 asthma Diseases 0.000 title claims abstract 5
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 229940021599 formoterol and beclometasone Drugs 0.000 title 1
- 229960002848 formoterol Drugs 0.000 claims abstract 9
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims abstract 9
- 229950000210 beclometasone dipropionate Drugs 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000012453 solvate Substances 0.000 claims abstract 6
- 238000009115 maintenance therapy Methods 0.000 claims abstract 4
- 208000023819 chronic asthma Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 208000024710 intermittent asthma Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims 11
- 239000003380 propellant Substances 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 5
- 229940071648 metered dose inhaler Drugs 0.000 claims 5
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical group O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 239000003911 antiadherent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the use of a composition comprising a fixed combination of a) formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate; for the manufacture of a medicament for use in the prevention and/or treatment of an exacerbation of asthma, intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.
Claims (27)
1. Use of a composition comprising a fixed combination of a) formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate;
for the manufacture of a medicament for use in the prevention and/or treatment of an exacerbation of asthma, intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.
for the manufacture of a medicament for use in the prevention and/or treatment of an exacerbation of asthma, intermittent asthma and/or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.
2. Use according to claim 1, wherein the molar ratio of (a) to (b), calculated as formoterol to beclometasone dipropionate, is from 1:1 to 1:500.
3. Use according to claim 2, wherein the molar ratio of (a) to (b), calculated as formoterol to beclometasone dipropionate, is from 1:1 to 1:100.
4. Use according to claim 3, wherein the molar ratio of (a) to (b), calculated as formoterol to beclometasone dipropionate, is from 1:3 to 1:30.
5. Use according to claim 4, wherein the molar ratio of (a) to (b), calculated as formoterol to beclometasone dipropionate, is 1:12.8.
6. Use according to claim 4, wherein the molar ratio of (a) to (b), calculated as formoterol to beclometasone dipropionate, is 1:25.6.
7. Use according to any one of claims 1 to 6 wherein the first active ingredient is formoterol fumarate dihydrate.
8. Use according to any one of claims 1 to 6 wherein the first active ingredient is the R,R-enantiomer of formoterol or pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt.
9. Use according to any previous claim wherein the daily dose of formoterol for adults, including maintenance therapy, may be as high as 168 microgram, preferably 100 microgram, and more preferably 84 microgram and even more preferably 72 microgram.
10. Use according to any previous claim wherein the daily dose of beclometasone dipropionate for adults, including maintenance therapy, may be as high as 5600, preferably 2800 microgram, more preferably 2400 microgram, even more preferably 1400 and most preferably 1200 microgram.
11. Use according to any previous claim, wherein the composition is administered by inhalation orally or intranasally.
12. Use according to claim 11, wherein the combination is administered by a dry powder inhaler, a pressurized metered dose inhaler, or a nebuliser.
13. Use according to claim 12, wherein the combination is formulated in form of a dry powder composition and may comprise one or more suitable diluents or carriers such as lactose, dextran, mannitol or glucose and preferably alpha-lactose monohydrate.
14. Use according to claim 13, wherein both the active ingredients (a) and (b) of the combination and the diluent/carrier may be in a micronized form.
15. Use according to claim 14, wherein a coarse diluent/carrier may be added to the composition to form an ordered mixture
16. Use according to claim 15, wherein said ordered mixture may optionally contain an additive to promote the release of the active ingredients selected from substances with anti-adherent, glidant or lubricant properties such as magnesium stearate.
17. Use according to claim 12, wherein the combination is formulated in the form of a pressurized metered dose inhaler and wherein both the active ingredients (a) and (b) in micronized form are suspended in a liquid propellant mixture.
18. Use according to claim 12, wherein the combination is formulated in the form of a pressurized metered dose inhaler and wherein one of the two active ingredient is suspended and the other is completely dissolved in a liquid propellant mixture.
19. Use according to claim 12, wherein the combination is formulated in the form of a pressurized metered dose inhaler wherein both the active ingredients (a) and (b) are completely dissolved in a liquid propellant mixture.
20. Use according to claim 19, wherein the liquid propellant mixture comprises HFA 134a (1,1,1,2-tetrafluoroethane), HFA 227 (1,1,1,2,3,3,3-heptafluoropropane) or their mixtures, optionally in combination with one or more cosolvent, surfactant, lubricant, antioxidant, stabilizing and or preserving agent.
21. Use according to claim 20, wherein the liquid propellant mixture comprises HFA 134a (1,1,1,2-tetrafluoroethane), ethanol as a cosolvent and an aqueous mineral acid as stabilising agent.
22. Use according to claim 21, wherein the aqueous mineral acid is 1M
hydrochloric acid.
hydrochloric acid.
23. Use according to any one of claims 19 to 22 which upon actuation of the pressurized metered dose inhaler, on evaporation of the propellant mixture, feature an average particle size of the two active ingredients equal or below 1.1 micrometer.
24. Use according to claim 12, wherein the combination is formulated in the form of a nebulizer either as a unit dose or multidose formulation.
25. Use according to claim 24, wherein both the active ingredients (a) and (b), in micronized form are suspended to give a nebulized aqueous or hydroalcoholic suspension with or without suitable pH or tonicity adjustment and optional addition of stabilizing and or preserving agent.
26. Use according to claim 25, wherein both the active ingredients (a) and (b) are dissolved to give a nebulized aqueous or hydroalcoholic solution with or without suitable pH or tonicity adjustment and optional addition of stabilizing and or preserving agent.
27. Use according to claim 24, wherein one of the two active ingredient is suspended and the other is completely dissolved to give a nebulized aqueous or hydroalcoholic suspension with or without suitable pH or tonicity adjustment and optional addition of stabilizing and or preserving agent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07007930.6 | 2007-04-19 | ||
| EP07007930A EP1982709A1 (en) | 2007-04-19 | 2007-04-19 | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| PCT/EP2008/003012 WO2008128685A1 (en) | 2007-04-19 | 2008-04-16 | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2684539A1 true CA2684539A1 (en) | 2008-10-30 |
Family
ID=38458097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002684539A Abandoned CA2684539A1 (en) | 2007-04-19 | 2008-04-16 | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20080261932A1 (en) |
| EP (3) | EP1982709A1 (en) |
| JP (2) | JP5492072B2 (en) |
| KR (3) | KR101668203B1 (en) |
| CN (1) | CN101657191B (en) |
| AU (1) | AU2008241045C1 (en) |
| BR (1) | BRPI0809800A2 (en) |
| CA (1) | CA2684539A1 (en) |
| CO (1) | CO6220945A2 (en) |
| CY (1) | CY1117568T1 (en) |
| DK (1) | DK2146704T3 (en) |
| EA (1) | EA018589B1 (en) |
| ES (2) | ES2740103T3 (en) |
| GE (1) | GEP20145999B (en) |
| HK (1) | HK1137357A1 (en) |
| HR (1) | HRP20160588T1 (en) |
| HU (1) | HUE029263T2 (en) |
| IL (1) | IL201632A (en) |
| MA (1) | MA31315B1 (en) |
| ME (1) | ME00945B (en) |
| MX (1) | MX2009010851A (en) |
| MY (1) | MY169579A (en) |
| NZ (1) | NZ580526A (en) |
| PL (2) | PL2146704T3 (en) |
| RS (1) | RS54874B1 (en) |
| SI (1) | SI2146704T1 (en) |
| TN (1) | TN2009000390A1 (en) |
| TR (1) | TR201909857T4 (en) |
| UA (1) | UA100237C2 (en) |
| WO (1) | WO2008128685A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982709A1 (en) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| DK2482799T3 (en) * | 2009-10-02 | 2014-09-01 | Chiesi Farma Spa | PHARMACEUTICAL AEROSOL FORMULATIONS OF FORMOTEROL AND BECLOMETASONDIPROPIONATE |
| CN102247597B (en) * | 2010-05-19 | 2015-01-07 | 天津金耀集团有限公司 | Novel inhalant containing glucocorticoid and bronchodilator |
| ES2938466T3 (en) * | 2012-01-25 | 2023-04-11 | Chiesi Farm Spa | Dry powder formulation comprising a corticosteroid and a beta-adrenergic agent for administration by inhalation |
| US11052202B2 (en) * | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
| WO2018051131A1 (en) * | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN107233311B (en) * | 2017-06-27 | 2020-12-04 | 长风药业股份有限公司 | Atomizing agent with arformoterol and glycopyrronium bromide as active ingredients and preparation method thereof |
| WO2024097413A1 (en) * | 2022-11-03 | 2024-05-10 | Dana-Farber Cancer Institute, Inc. | Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| DE69232462T2 (en) | 1991-12-18 | 2002-10-10 | Astrazeneca Ab | COMPOSITION CONTAINING FORMOTEROL AND BUDESONIDE |
| SE9802073D0 (en) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| ME00220B (en) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| FI20002177A0 (en) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | New combination for asthma therapy |
| FI20002216A0 (en) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Combination particles for asthma therapy |
| FI20002215A0 (en) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Combination Particles |
| ATE465712T1 (en) | 2002-03-01 | 2010-05-15 | Chiesi Farma Spa | ULTRAFINE COMPOSITIONS OF FORMOTEROL |
| EP1982709A1 (en) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
-
2007
- 2007-04-19 EP EP07007930A patent/EP1982709A1/en not_active Withdrawn
-
2008
- 2008-04-16 KR KR1020157005890A patent/KR101668203B1/en active IP Right Grant
- 2008-04-16 MX MX2009010851A patent/MX2009010851A/en active IP Right Grant
- 2008-04-16 UA UAA200909905A patent/UA100237C2/en unknown
- 2008-04-16 KR KR1020097019229A patent/KR20100014408A/en not_active IP Right Cessation
- 2008-04-16 PL PL08748930.8T patent/PL2146704T3/en unknown
- 2008-04-16 NZ NZ580526A patent/NZ580526A/en unknown
- 2008-04-16 MY MYPI20094314A patent/MY169579A/en unknown
- 2008-04-16 DK DK08748930.8T patent/DK2146704T3/en active
- 2008-04-16 GE GEAP200811515A patent/GEP20145999B/en unknown
- 2008-04-16 HU HUE08748930A patent/HUE029263T2/en unknown
- 2008-04-16 WO PCT/EP2008/003012 patent/WO2008128685A1/en active Application Filing
- 2008-04-16 AU AU2008241045A patent/AU2008241045C1/en active Active
- 2008-04-16 KR KR1020157017841A patent/KR101621676B1/en active IP Right Grant
- 2008-04-16 EA EA200901201A patent/EA018589B1/en not_active IP Right Cessation
- 2008-04-16 CN CN200880012407.9A patent/CN101657191B/en active Active
- 2008-04-16 ES ES16152451T patent/ES2740103T3/en active Active
- 2008-04-16 TR TR2019/09857T patent/TR201909857T4/en unknown
- 2008-04-16 EP EP08748930.8A patent/EP2146704B1/en active Active
- 2008-04-16 EP EP16152451.7A patent/EP3034073B1/en active Active
- 2008-04-16 SI SI200831597A patent/SI2146704T1/en unknown
- 2008-04-16 BR BRPI0809800-0A2A patent/BRPI0809800A2/en not_active Application Discontinuation
- 2008-04-16 ME MEP-2009-315A patent/ME00945B/en unknown
- 2008-04-16 RS RS20160439A patent/RS54874B1/en unknown
- 2008-04-16 ES ES08748930.8T patent/ES2568497T3/en active Active
- 2008-04-16 PL PL16152451T patent/PL3034073T3/en unknown
- 2008-04-16 JP JP2010503394A patent/JP5492072B2/en active Active
- 2008-04-16 CA CA002684539A patent/CA2684539A1/en not_active Abandoned
- 2008-04-21 US US12/106,493 patent/US20080261932A1/en not_active Abandoned
-
2009
- 2009-09-24 TN TNP2009000390A patent/TN2009000390A1/en unknown
- 2009-10-13 CO CO09113200A patent/CO6220945A2/en not_active Application Discontinuation
- 2009-10-15 MA MA32284A patent/MA31315B1/en unknown
- 2009-10-19 IL IL201632A patent/IL201632A/en active IP Right Grant
-
2010
- 2010-04-09 HK HK10103496.1A patent/HK1137357A1/en unknown
-
2013
- 2013-10-18 JP JP2013217531A patent/JP2014005312A/en not_active Withdrawn
-
2016
- 2016-04-14 CY CY20161100313T patent/CY1117568T1/en unknown
- 2016-06-01 HR HRP20160588TT patent/HRP20160588T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2684539A1 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| AU2011278096B2 (en) | Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators | |
| JP2010519195A (en) | Pharmaceutical composition | |
| NZ536279A (en) | Use of a composition comprising formoterol and budesonide for symptomatic relief, when needed, in the prevention or treatment of an acute condition of asthma | |
| US20150250713A1 (en) | Pharmaceutical Composition | |
| SK285884B6 (en) | Combined preparation of formoterol and tiotropium salt, its use and pharmaceutical kit comprising the same | |
| CA2409660A1 (en) | Novel process | |
| WO2012049444A1 (en) | Pharmaceutical composition | |
| WO2014016548A2 (en) | Pharmaceutical composition | |
| US20070167496A1 (en) | Roflumilast and glycopyrronium combination | |
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| WO2004084896A1 (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases | |
| US20160310410A1 (en) | Pharmaceutical compositions comprising arformoterol and glycopyrronium | |
| US20060189642A1 (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases | |
| AU2017276321A1 (en) | Pharmaceutical composition comprising arformoterol and fluticasone furoate | |
| WO2012010854A1 (en) | Inhalation formulations comprising carmoterol in combination with a corticosteroid | |
| WO2012093252A1 (en) | Pharmaceutical composition | |
| CA2456721A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| WO2004084894A1 (en) | Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases | |
| WO2015063669A1 (en) | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof | |
| EP2911649A2 (en) | Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130404 |
|
| FZDE | Discontinued |
Effective date: 20160525 |